High soluble OX40 levels correlate with metastatic gastric cancer

• Published in: Journal of surgical oncology 2022-07, Vol.126 (1), p.139-143
• Main Authors: Lima, Cecilia A. C., Martins, Mário R., Santos, Rogerio L., Silva, Luciana M., Silva, Jeronimo P. A., Torres, Leuridan C., Forones, Nora M.
• Format: Article
• Language: English
• Subjects: Biomarkers - metabolism; Cross-Sectional Studies; Gastric cancer; Humans; immunotherapy; Metastasis; soluble OX40; Stomach Neoplasms - metabolism; T-Lymphocytes - metabolism
• ISSN: 0022-4790; 1096-9098
• DOI: 10.1002/jso.26856

Background and Objectives Previous studies demonstrated an association between OX40+T cell expression with poor prognosis in gastric cancer (GC). The soluble form of OX40 (sOX40) could block the interactions between OX40 on the effector T cell, and it is a ligand (OX40L) in dendritic cells. However, the role of sOX40 as a pretreating biomarker and prognostic predictor remains unclear. This study aimed to evaluate the association of levels of sOX40 and sOX40L with disease progression in GC. Methods Between 2017 and 2018, a cross‐sectional study was performed on 83 GC patients and 20 healthy controls. Results Among 83 GC patients (median of 63 years), 32.4% of patients with I/II stages, 42.3% III, and 25.3% in IV stages. Metastatic GC patients had significantly higher levels of soluble OX40 compared with stage III (p = 0.0003) and early stages I and II patients (p = 0.005). There was no significant differences in the sOX40 and sOX40L levels between Lauren's histological subtype (intestinal, diffuse, and mixed). Conclusions This study showed that soluble OX40 levels have an essential role in GC progression. OX40 molecules may constitute a predictor for poor prognosis and a potential target for immunotherapy in GC.